Hexarelin
Potent growth hormone releasing peptide with cardioprotective effects
🛑 WADA Banned 19 views
🛑 WADA BANNED - Prohibited in competitive sports as potent growth hormone releasing agent
Overview
Hexarelin (Examorelin) is a synthetic hexapeptide growth hormone secretagogue that demonstrates unique dual activity: potent GH stimulation through ghrelin receptor activation and distinct cardioprotective effects through CD36 receptor binding. Research shows Hexarelin produces the strongest GH release among the GHRP family peptides, though it is subject to desensitization with prolonged use. The cardioprotective properties are independent of GH release and involve direct effects on cardiac tissue, including improved contractility, reduced apoptosis, and protection against ischemia-reperfusion injury. Studies demonstrate Hexarelin may improve cardiac function in heart failure models and protect against doxorubicin-induced cardiotoxicity. The peptide has been investigated for both growth hormone deficiency and cardiovascular applications. Like other GHRPs, Hexarelin increases appetite and produces modest elevations in cortisol and prolactin. Administration requires subcutaneous injection, and cycling protocols are often recommended to prevent receptor desensitization. The unique cardiac benefits distinguish Hexarelin from other growth hormone secretagogues.

Quick Facts
Formula:C47H58N12O6
Molecular Weight:887.04
Sequence:His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2
Mechanism:Synthetic hexapeptide with strong GH-releasing activity
⚠️ Safety Information
Research compound only. Limited human safety data available.
Research Citations
Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
Massoud AF, Hindmarsh PC, Brook CG (1997)
The cardiovascular action of hexarelin.
Mao Y, Tokudome T, Kishimoto I (2014)
Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway.
Guan C, Li C, Shen X, Yang C, Liu Z, Zhang N, Xu L, Zhao L, Zhou B, Man X, Luo C, Luan H, Che L, Wang Y, Xu Y (2023)
Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation.
Jiang B, Wang M, Li X, Ren P, Li G, Wang Y, Wang L, Li X, Yang D, Qin L, Xin S (2022)
+ 21 more citations